The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products. The 2024 Symposium will explore how to continue to adapt concepts applied to other biologics and how to establish novel approaches where they are needed. The Symposium will be offered in-person as well as live streamed to a virtual audience.
We’re looking forward to connecting and to the potential of supporting your program. Schedule a meeting while at the show here.
BioTechLogic, Inc., is a biopharmaceutical manufacturing and CMC consulting firm with strategic and practical/hands-on experience that helps clients bring their products to market quickly and successfully by augmenting and optimizing an organization's technical, manufacturing, analytical, and regulatory resources.
Article originally published on GEN The biotechnology industry achieved many firsts this past year, from the first approved drug that can slow the rates of cognitive and functional decline in adults with Alzheimer’s disease, to the first CRISPR-based gene editing...
Originally posted on Regulatory Focus - a RAPS publication The new EU Clinical Trials Regulation represents the most significant overhaul of clinical trial requirements in Europe for a generation, and this article describes the insight gained during the months...
© 2024 BIOTECHLOGIC, INC | ALL RIGHTS RESERVED